NKGen Biotech (NKGN) Competitors

ImmunoPrecise Antibodies (NASDAQ:IPA) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Which has more volatility and risk, IPA or NKGN?

ImmunoPrecise Antibodies has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Which has preferable earnings & valuation, IPA or NKGN?

ImmunoPrecise Antibodies has higher revenue and earnings than NKGen Biotech. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunoPrecise Antibodies	$18.16M	2.80	-$20.13M	-$1.16	-0.96
NKGen Biotech	$80K	134.96	-$82.94M	-$2.45	-0.10

Do insiders and institutionals have more ownership in IPA or NKGN?

6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are held by company insiders. Comparatively, 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media refer more to IPA or NKGN?

In the previous week, ImmunoPrecise Antibodies had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 2 mentions for ImmunoPrecise Antibodies and 1 mentions for NKGen Biotech. ImmunoPrecise Antibodies' average media sentiment score of 0.94 beat NKGen Biotech's score of 0.00 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunoPrecise Antibodies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NKGen Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is IPA or NKGN more profitable?

NKGen Biotech has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -190.76%. NKGen Biotech's return on equity of 0.00% beat ImmunoPrecise Antibodies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunoPrecise Antibodies	-190.76%	-88.87%	-49.26%
NKGen Biotech	N/A	N/A	-479.36%

Do analysts prefer IPA or NKGN?

ImmunoPrecise Antibodies currently has a consensus price target of $4.00, indicating a potential upside of 260.36%. Given ImmunoPrecise Antibodies' stronger consensus rating and higher possible upside, equities research analysts plainly believe ImmunoPrecise Antibodies is more favorable than NKGen Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunoPrecise Antibodies	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

ImmunoPrecise Antibodies beats NKGen Biotech on 9 of the 16 factors compared between the two stocks.